Published in J Clin Oncol on June 01, 1995
Chemotherapy for colorectal carcinoma: one small step forward, one step backward. J Clin Oncol (1995) 2.16
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer (1999) 1.27
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression. Clin Exp Immunol (2001) 1.07
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer (1997) 1.05
Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer (1997) 0.86
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study. Br J Cancer (1998) 0.83
Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer (1998) 0.82
A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Br J Cancer (1997) 0.80
A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer. Br J Cancer (1999) 0.79
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. Br J Cancer (1996) 0.78
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer (2001) 0.76
Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. Br J Cancer (2001) 0.75
Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. Br J Cancer (1996) 0.75
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study. Invest New Drugs (2004) 0.75
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
On the Interpretation of Multi-Hit Survival Curves. Proc Natl Acad Sci U S A (1949) 5.96
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
The partition of CO(2) between plasma and corpuscles in oxygenated and reduced blood. J Physiol (1920) 5.63
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Insulin biosynthesis: evidence for a precursor. Science (1967) 5.05
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet (2001) 5.01
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Biotechnology awareness study, Part 1: Where scientists get their information. Bull Med Libr Assoc (1991) 3.85
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res (2000) 3.41
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer (1998) 3.36
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) 3.33
Effect of reactive pharmacy intervention on quality of hospital prescribing. BMJ (1990) 3.25
Heterogeneity of microsatellite mutations within and between loci, and implications for human demographic histories. Genetics (1998) 3.12
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer (2004) 3.03
The reduction of surgical wound infections by prophylactic parenteral cephaloridine. A controlled clinical trial. Br J Surg (1973) 2.99
Genetic manipulation of centromere function. Mol Cell Biol (1987) 2.97
The emerging role of the emergency care practitioner. Emerg Med J (2004) 2.95
Equatorius: a new hominoid genus from the Middle Miocene of Kenya. Science (1999) 2.92
Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet (1985) 2.88
Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol (1992) 2.88
C-type virus released from cultured human rhabdomyosarcoma cells. Nat New Biol (1972) 2.78
Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(®)) Society recommendations. World J Surg (2013) 2.77
Service profiling and outcomes benchmarking using the CORE-OM: toward practice-based evidence in the psychological therapies. Clinical Outcomes in Routine Evaluation-Outcome Measures. J Consult Clin Psychol (2001) 2.72
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol (1997) 2.71
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta (1975) 2.64
Parents' accounts of obtaining a diagnosis of childhood cancer. Lancet (2001) 2.62
Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension (2000) 2.55
Failure of early diagnosis in symptomatic Duchenne muscular dystrophy. Lancet (1999) 2.49
Identification of the class I genes of the mouse major histocompatibility complex by DNA-mediated gene transfer. Nature (1982) 2.48
Radiographic interpretation by nurse practitioners in a minor injuries unit. J Accid Emerg Med (1996) 2.44
Is a low leptin concentration, a low resting metabolic rate, or both the expression of the "thrifty genotype"? Results from Mexican Pima Indians. Am J Clin Nutr (1998) 2.42
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol (2005) 2.41
Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab (1996) 2.40
Validation of the Arizona Activity Frequency Questionnaire using doubly labeled water. Med Sci Sports Exerc (2001) 2.40
Phenomics: the systematic study of phenotypes on a genome-wide scale. Neuroscience (2009) 2.38
The use of out of hours health services: a cross sectional survey. BMJ (1998) 2.36
Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med (1996) 2.35
Bile acid transformations by microbial strains belonging to genera found in intestinal contents. Acta Pathol Microbiol Scand (1967) 2.33
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Perinatal hypoxic-ischemic thalamic injury: clinical features and neuroimaging. Ann Neurol (1998) 2.29
ELECTROCARDIOGRAPHIC CHANGES AFTER ANOXAEMIA AND EXERCISE IN ANGINA OF EFFORT. Br Heart J (1941) 2.26
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr (2012) 2.25
From quantity to quality: the central cardiac audit database project. Heart (1999) 2.23
Chromatin conformation of yeast centromeres. J Cell Biol (1984) 2.19
Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet (1995) 2.17
Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events. J Virol (2001) 2.13
Management of carcinomas of the upper gastrointestinal tract. BMJ (1994) 2.12
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 2.12
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer (1996) 2.11
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol (1996) 2.08
Polycystic kidney disease re-evaluated: a population-based study. Q J Med (1991) 2.05
Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci U S A (1996) 2.03
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study. Eur Heart J (1995) 1.97
Measles, mumps, and rubella vaccination. BMJ (1992) 1.96
Osteoporosis in patients with inflammatory bowel disease. Gut (1987) 1.95
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Replication-defective chimeric helper proviruses and factors affecting generation of competent virus: expression of Moloney murine leukemia virus structural genes via the metallothionein promoter. Mol Cell Biol (1987) 1.94
Uroradiology: imaging in prostate cancer. Clin Radiol (2001) 1.93
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore) (1991) 1.89
Magnetic resonance imaging volumes of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. Arch Gen Psychiatry (2000) 1.88
In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum (1997) 1.87
Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther (1997) 1.86
Reproducibility of measurements of oestrogen-receptor concentration in breast cancer. Br J Cancer (1977) 1.85
Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med (Berl) (1998) 1.83
Emphysematous pyelonephritis in diabetic patients. Br J Urol (1995) 1.82
The milk-ejection reflex of the rat: an intermittent function not abolished by surgical levels of anaesthesia. J Endocrinol (1973) 1.82
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer (2005) 1.81
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80